Progress toward a group B streptococcal vaccine

Joon-Young Song, Jae Hyang Lim, Sangyong Lim, Zhi Yong, Ho Seong Seo

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Streptococcus agalactiae (group B Streptococcus, GBS) is a leading cause of severe invasive disease in neonate, elderly, and immunocompromised patients worldwide. Despite recent advances in the diagnosis and intrapartum antibiotic prophylaxis (IAP) of GBS infections, it remains one of the most common causes of neonatal morbidity and mortality, causing serious infections. Furthermore, recent studies reported an increasing number of GBS infections in pregnant women and elderly. Although IAP is effective, it has several limitations, including increasing antimicrobial resistance and late GBS infection after negative antenatal screening. Maternal immunization is the most promising and effective countermeasure against GBS infection in neonates. However, no vaccine is available to date, but two types of vaccines, protein subunit and capsular polysaccharide conjugate vaccines, were investigated in clinical trials. Here, we provide an overview of the GBS vaccine development status and recent advances in the development of immunoassays to evaluate the GBS vaccine clinical efficacy.

Original languageEnglish
Pages (from-to)2669-2681
Number of pages13
JournalHuman Vaccines and Immunotherapeutics
Volume14
Issue number11
DOIs
Publication statusPublished - 2018 Nov 2

Fingerprint

Streptococcal Vaccines
Streptococcus agalactiae
Vaccines
Infection
Antibiotic Prophylaxis
Newborn Infant
Conjugate Vaccines
Protein Subunits
Immunocompromised Host
Infant Mortality
Streptococcus
Prenatal Diagnosis
Immunoassay
Polysaccharides
Pregnant Women
Immunization
Mothers
Clinical Trials

Keywords

  • group B Streptococcus
  • maternal immunization
  • Streptococcus agalactiae
  • vaccine

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology

Cite this

Progress toward a group B streptococcal vaccine. / Song, Joon-Young; Lim, Jae Hyang; Lim, Sangyong; Yong, Zhi; Seo, Ho Seong.

In: Human Vaccines and Immunotherapeutics, Vol. 14, No. 11, 02.11.2018, p. 2669-2681.

Research output: Contribution to journalReview article

Song, Joon-Young ; Lim, Jae Hyang ; Lim, Sangyong ; Yong, Zhi ; Seo, Ho Seong. / Progress toward a group B streptococcal vaccine. In: Human Vaccines and Immunotherapeutics. 2018 ; Vol. 14, No. 11. pp. 2669-2681.
@article{dfe0f9e794c74b4b8c6f1c71a4a95116,
title = "Progress toward a group B streptococcal vaccine",
abstract = "Streptococcus agalactiae (group B Streptococcus, GBS) is a leading cause of severe invasive disease in neonate, elderly, and immunocompromised patients worldwide. Despite recent advances in the diagnosis and intrapartum antibiotic prophylaxis (IAP) of GBS infections, it remains one of the most common causes of neonatal morbidity and mortality, causing serious infections. Furthermore, recent studies reported an increasing number of GBS infections in pregnant women and elderly. Although IAP is effective, it has several limitations, including increasing antimicrobial resistance and late GBS infection after negative antenatal screening. Maternal immunization is the most promising and effective countermeasure against GBS infection in neonates. However, no vaccine is available to date, but two types of vaccines, protein subunit and capsular polysaccharide conjugate vaccines, were investigated in clinical trials. Here, we provide an overview of the GBS vaccine development status and recent advances in the development of immunoassays to evaluate the GBS vaccine clinical efficacy.",
keywords = "group B Streptococcus, maternal immunization, Streptococcus agalactiae, vaccine",
author = "Joon-Young Song and Lim, {Jae Hyang} and Sangyong Lim and Zhi Yong and Seo, {Ho Seong}",
year = "2018",
month = "11",
day = "2",
doi = "10.1080/21645515.2018.1493326",
language = "English",
volume = "14",
pages = "2669--2681",
journal = "Human Vaccines and Immunotherapeutics",
issn = "2164-5515",
publisher = "Landes Bioscience",
number = "11",

}

TY - JOUR

T1 - Progress toward a group B streptococcal vaccine

AU - Song, Joon-Young

AU - Lim, Jae Hyang

AU - Lim, Sangyong

AU - Yong, Zhi

AU - Seo, Ho Seong

PY - 2018/11/2

Y1 - 2018/11/2

N2 - Streptococcus agalactiae (group B Streptococcus, GBS) is a leading cause of severe invasive disease in neonate, elderly, and immunocompromised patients worldwide. Despite recent advances in the diagnosis and intrapartum antibiotic prophylaxis (IAP) of GBS infections, it remains one of the most common causes of neonatal morbidity and mortality, causing serious infections. Furthermore, recent studies reported an increasing number of GBS infections in pregnant women and elderly. Although IAP is effective, it has several limitations, including increasing antimicrobial resistance and late GBS infection after negative antenatal screening. Maternal immunization is the most promising and effective countermeasure against GBS infection in neonates. However, no vaccine is available to date, but two types of vaccines, protein subunit and capsular polysaccharide conjugate vaccines, were investigated in clinical trials. Here, we provide an overview of the GBS vaccine development status and recent advances in the development of immunoassays to evaluate the GBS vaccine clinical efficacy.

AB - Streptococcus agalactiae (group B Streptococcus, GBS) is a leading cause of severe invasive disease in neonate, elderly, and immunocompromised patients worldwide. Despite recent advances in the diagnosis and intrapartum antibiotic prophylaxis (IAP) of GBS infections, it remains one of the most common causes of neonatal morbidity and mortality, causing serious infections. Furthermore, recent studies reported an increasing number of GBS infections in pregnant women and elderly. Although IAP is effective, it has several limitations, including increasing antimicrobial resistance and late GBS infection after negative antenatal screening. Maternal immunization is the most promising and effective countermeasure against GBS infection in neonates. However, no vaccine is available to date, but two types of vaccines, protein subunit and capsular polysaccharide conjugate vaccines, were investigated in clinical trials. Here, we provide an overview of the GBS vaccine development status and recent advances in the development of immunoassays to evaluate the GBS vaccine clinical efficacy.

KW - group B Streptococcus

KW - maternal immunization

KW - Streptococcus agalactiae

KW - vaccine

UR - http://www.scopus.com/inward/record.url?scp=85058711073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058711073&partnerID=8YFLogxK

U2 - 10.1080/21645515.2018.1493326

DO - 10.1080/21645515.2018.1493326

M3 - Review article

C2 - 29995578

AN - SCOPUS:85058711073

VL - 14

SP - 2669

EP - 2681

JO - Human Vaccines and Immunotherapeutics

JF - Human Vaccines and Immunotherapeutics

SN - 2164-5515

IS - 11

ER -